Tumor News and Research RSS Feed - Tumor News and Research

LSU Health researchers reveal how Chop plays crucial role to combat cancer

LSU Health researchers reveal how Chop plays crucial role to combat cancer

Research led by Paulo Rodriguez, PhD, an assistant research professor of Microbiology, Immunology & Parasitology at LSU Health New Orleans' Stanley S. Scott Cancer Center, has identified the crucial role an inflammatory protein known as Chop plays in the body's ability to fight cancer. [More]
Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

Exercise may have added benefit for cancer patients undergoing chemotherapy: Study

Study after study has proven it true: exercise is good for you. But new research from University of Pennsylvania scientists suggests that exercise may have an added benefit for cancer patients undergoing chemotherapy. [More]
Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Penn Medicine, Wistar Institute awarded NCI grants for four new melanoma research projects

Penn Medicine and The Wistar Institute have been awarded a prestigious $12.1 million SPORE grant from the National Cancer Institute. The five-year Specialized Programs of Research Excellence, or SPORE, grant will fund four new melanoma research projects that aim to translate fundamental laboratory discoveries into new therapeutics to treat melanoma and other skin cancers. [More]
ICO-IDIBELL researchers identify 5 genes differentially expressed in colorectal tumors

ICO-IDIBELL researchers identify 5 genes differentially expressed in colorectal tumors

Researchers at the Catalan Institute of Oncology-Bellvitge Biomedical Research Institute, led by David Garcia-Mollev- have identified 5 genes differentially expressed in normal accompanying cells in colorectal tumors. [More]
Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

Radiation and endocrine therapy combination may not be necessary for all HR+ breast cancer patients

Treatment with endocrine therapy and radiation therapy as part of breast conservation is the current standard of care for women with hormone-receptor positive (HR+) invasive breast cancer. A new study by researchers at Fox Chase Cancer Center, however, shows that combination may not be necessary for all patient populations with the disease. [More]
Current smokers at increased risk of developing SPLC

Current smokers at increased risk of developing SPLC

Non-small cell lung cancer (NSCLC) survivors who never smoked or who are former smokers at the time of diagnosis have a lower risk of developing secondary primary lung cancers (SPLC) compared to those who are current smokers, suggesting that increased tobacco exposure is associated with a higher risk of SPLC, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. [More]
UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

UCSD researchers launch phase 1 trial to assess novel monoclonal antibody for CLL patients

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults. [More]
Zebrafish may hold key to unlocking a leading cause of respiratory diseases

Zebrafish may hold key to unlocking a leading cause of respiratory diseases

A small freshwater fish found in many tropical aquariums may hold the key to unlocking one of the leading causes of respiratory diseases in humans. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Denovo gains all rights from Lilly to develop, manufacture and commercialize enzastaurin drug

Denovo Biopharma, LLC, today announced that it has acquired enzastaurin, a late-stage oncology drug, from Eli Lilly and Company. Denovo gains all rights to develop, manufacture and commercialize enzastaurin globally, including transfer of all intellectual property and other rights, data, and information. [More]
Scientists develop new method to get clearer picture of how drug abuse affects the brain

Scientists develop new method to get clearer picture of how drug abuse affects the brain

One thing leads to another, especially in research. When Stony Brook University School of Medicine scientists developed a new method to measure how cocaine disrupts blood flow in the brains of mice, doctors and researchers got a way to form a clearer picture of how drug abuse affects the brain. [More]
Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

Specific blood test could indicate neoadjuvant treatment regimens for ESCC patients

A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma (ESCC), according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. [More]
RT alone effective in decreasing dysphagia in patients with advanced esophageal cancer

RT alone effective in decreasing dysphagia in patients with advanced esophageal cancer

Radiation therapy (RT) alone is as effective in decreasing swallowing complications experienced by advanced esophageal cancer patients as RT combined with chemotherapy, thus allowing patients to forgo chemotherapy, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting. [More]
Cancer-fighting cocktail shows promising results for advanced cervical cancer

Cancer-fighting cocktail shows promising results for advanced cervical cancer

Combining a standard chemotherapy drug with a second drug that stops cells from dividing improves both the survival and response rates for those with advanced cervical cancer, a new study by UT Southwestern Medical Center cancer researchers finds. [More]
Collaborative study takes important step toward finding targeted treatments for bladder cancer

Collaborative study takes important step toward finding targeted treatments for bladder cancer

The story of cancer care seems so simple: find the mutated gene that causes cancer and turn it off or fix it. But rarely does a single gene cause cancer. More often, many genes are altered together to drive the disease. So the challenge becomes sorting out which altered genes are the most to blame in which cancers. [More]
Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival. [More]
GILZ protein key to preventing bone loss, researchers report

GILZ protein key to preventing bone loss, researchers report

A small protein named GILZ appears to protect against the bone loss that often accompanies arthritis and its treatment, researchers report. [More]
Researchers find learning and memory components of neurofibromatosis using zebrafish model

Researchers find learning and memory components of neurofibromatosis using zebrafish model

Using a zebrafish model of a human genetic disease called neurofibromatosis (NF1), a team from the Perelman School of Medicine at the University of Pennsylvania has found that the learning and memory components of the disorder are distinct features that will likely need different treatment approaches. [More]
Broach Foundation makes $5 million commitment to support glioblastoma multiforme research

Broach Foundation makes $5 million commitment to support glioblastoma multiforme research

The Broach Foundation for Brain Cancer Research has made a $5 million commitment to support glioblastoma multiforme research at The University of Texas MD Anderson Cancer Center. [More]

IMRIS receives FDA clearance for new neurosurgical HFD rocker arm

IMRIS Inc. today announced a new rocker arm accessory that expands choices for neurosurgeons to select the best fixation suited for patients during procedures using intraoperative imaging inside the VISIUS Surgical Theatre. The accessory recently received 510(k) clearance from the U.S. Food and Drug Administration. [More]